These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 35887589)

  • 21. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different endotypes and phenotypes drive the heterogeneity in severe asthma.
    McDowell PJ; Heaney LG
    Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Advance of Personalized and Stratified Therapies in Bronchial Asthma: Phenotypes - Endotypes - Biomarkers.
    Lauer S; Renz H
    EJIFCC; 2013 Feb; 24(3):113-25. PubMed ID: 27683446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of Allergic, Eosinophilic, and Overlapping Asthma Phenotypes Among Pediatric Patients with Current Asthma: A Cross-Sectional Study from Saudi Arabia.
    Asseri AA
    J Asthma Allergy; 2023; 16():1297-1308. PubMed ID: 38058515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular T2 asthma phenotypes are stable but heterogeneous: the usefulness of periostin for endotyping.
    Bobolea I; Guillén-Vera D; De Las Cuevas-Moreno N; García-Granero DB; Loli-Ausejo D; Melero-Moreno C
    Front Allergy; 2023; 4():1205115. PubMed ID: 37744693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asthma phenotypes and endotypes: a personalized approach to treatment.
    Skloot GS
    Curr Opin Pulm Med; 2016 Jan; 22(1):3-9. PubMed ID: 26574717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
    Parulekar AD; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
    Chan R; RuiWen Kuo C; Lipworth B
    J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining phenotypes in asthma: a step towards personalized medicine.
    Chung KF
    Drugs; 2014 May; 74(7):719-28. PubMed ID: 24797157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Therapies for Emerging Endotypes of Asthma.
    Chupp GL; Kaur R; Mainardi A
    Annu Rev Med; 2020 Jan; 71():289-302. PubMed ID: 31689153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classification of non-acute bronchial asthma according to allergy and eosinophil characteristics: a retrospective study.
    Jiang Y; An R; Cheng L; Yue Q; Zhang H; Zhang Y; Kong X; Ma H; Chen F; Guo Y
    Allergy Asthma Clin Immunol; 2021 May; 17(1):45. PubMed ID: 33941235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of asthma endotypes and phenotypes.
    Taunk ST; Cardet JC; Ledford DK
    Allergy Asthma Proc; 2022 Sep; 43(5):375-382. PubMed ID: 36065106
    [No Abstract]   [Full Text] [Related]  

  • 34. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.
    Hamilton D; Lehman H
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):160-174. PubMed ID: 31359247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading.
    Bernstein JA; Panettieri R
    J Asthma; 2019 May; 56(5):459-472. PubMed ID: 29718738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the diagnosis of eosinophilic asthma.
    Coumou H; Bel EH
    Expert Rev Respir Med; 2016 Oct; 10(10):1093-103. PubMed ID: 27624868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents.
    Yilmaz İ
    Tuberk Toraks; 2019 Dec; 67(4):292-299. PubMed ID: 32050871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches for identifying and testing potential new anti-asthma agents.
    Licari A; Castagnoli R; Brambilla I; Marseglia A; Tosca MA; Marseglia GL; Ciprandi G
    Expert Opin Drug Discov; 2018 Jan; 13(1):51-63. PubMed ID: 29077521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic Therapy and Novel Molecular Targets of Severe Asthma.
    Pepper AN; Renz H; Casale TB; Garn H
    J Allergy Clin Immunol Pract; 2017; 5(4):909-916. PubMed ID: 28689841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.